AssetMark Inc
PDLI

AssetMark Inc’s PDL BioPharma, Inc. PDLI Stock Holding History

AssetMark Inc’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,581
Closed -$5K – 1500
2019
Q2 		$5K Buy
1,581
+421
+36% +$1.37K ﹤0.01% 1070
2019
Q1 		$4K Buy
1,160
+157
+16% +$530 ﹤0.01% 1104
2018
Q4 		$3K Sell
1,003
-728
-42% -$2K ﹤0.01% 1194
2018
Q3 		$5K Sell
1,731
-148
-8% -$363 ﹤0.01% 1188
2018
Q2 		$4K Sell
1,879
-59
-3% -$165 ﹤0.01% 1217
2018
Q1 		$6K Buy
1,938
+110
+6% +$300 ﹤0.01% 1143
2017
Q4 		$5K Buy
1,828
+1,683
+1,161% +$5.17K ﹤0.01% 1268
2017
Q3 		$0 Buy
145
+141
+3,525% +$392 ﹤0.01% 1705
2017
Q2 		$0 Buy
+4
New +$9 ﹤0.01% 1561
2017
Q1 		– Sell
-49
Closed – – 1544
2016
Q4 		$0 Buy
+49
New +$137 ﹤0.01% 1465

Other funds holding PDLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

AssetMark Inc's PDLI Position: Q3 2019 in Review

AssetMark Inc sold out of PDL BioPharma, Inc. (PDLI) in Q3 2019, closing a stake of 1,581 shares — an estimated $5K sold.

AssetMark Inc first reported a position in PDLI in Q4 2016 and held it in 10 quarters. The position peaked at $6K in Q1 2018. 140 funds tracked by Wall St. Rank hold PDLI as of Q3 2019.

  • AssetMark Inc reported no remaining PDL BioPharma, Inc. position as of Q3 2019 after selling out during the quarter.
  • AssetMark Inc sold 1,581 PDL BioPharma, Inc. shares in Q3 2019, an estimated $5K.
  • AssetMark Inc first reported a position in PDL BioPharma, Inc. in Q4 2016 and held it in 10 quarters.
  • AssetMark Inc's PDL BioPharma, Inc. position peaked at $6K in Q1 2018.
  • 140 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2019.

Based on AssetMark Inc's 13F filing for Q3 2019, filed 13 Nov 2019.